This site is intended for US healthcare professionals only.

    KaryForward™ patient support by Karyopharm

    Discover the benefits of KaryForward, a patient support program by Karyopharm Therapeutics® Inc. dedicated to providing assistance and resources to patients and their caregivers for XPOVIO® (selinexor) treatment.

    Insurance coverage icon

    Insurance Coverage

    Get assistance navigating the insurance process, including benefits investigations, claims assistance, prior authorizations, and appeals.

    • QuickStart Program: Gain rapid access to XPOVIO for patients who experience a delay in insurance coverage
    • Bridge Program: Get an emergency supply of free XPOVIO for patients who experience an unexpected disruption in therapy
    Financial assistance icon

    Financial Assistance

    Gain access to programs that can help your eligible patients with the cost of Karyopharm medications.

    • Patient Assistance Program: Patients who are uninsured or underinsured may be eligible to receive XPOVIO at
      no cost
    • XPOVIO Copay Program: Patients with commercial insurance may be eligible to pay as little as $5 for each XPOVIO prescription
    Support and resources icon

    Support and Resources

    Dedicated Nurse Case Managers can provide additional information about XPOVIO treatment such as:

    • Prescription instructions
    • Psychosocial support and additional nonclinical education
    • Highlight what to expect when taking Karyopharm medications and the importance of talking to healthcare providers about the treatment journey
    • Determine if additional third-party support is available such as transportation assistance
    To learn more, call 1-877-KARY4WD1-877-KARY4WD (1‑877‑527‑9493), Monday through Friday, 8 am to 8 pm ET, or visit KaryForward.com/hcp.

    Resources for healthcare professionals

    Tools and downloads

    Product information

    XPOVIO Brochure

    Learn why XPOVIO is FDA approved to help your adult patients with RRMM

    Download
    Patient Profiles

    Review profiles of eligible patients

    Download
    Getting Patients Started on XPOVIO for RRMM

    See recommended dosing schedule and dose modifications

    Download

    Ordering XPOVIO

    Product Information Fact Sheet

    See distribution information for XPOVIO

    Download

    Patient counseling and support

    Patient & Caregiver Brochure

    Get helpful information on XPOVIO for patients and caregivers

    Download [English] Download [Spanish]
    KaryForward Enrollment Form

    Enroll your patient in the KaryForward Patient Support Program

    Download
    Patient Daily Tracker

    A helpful tool for tracking medication as well as fluid and caloric intake

    Download [English] Download [Spanish]
    Caregiver Monthly Planner

    Keep track of monthly appointments

    Download [English] Download [Spanish]

    INDICATIONS

    • XPOVIO® (selinexor) in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.
    • XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

    IMPORTANT SAFETY INFORMATION

    Thrombocytopenia: XPOVIO can cause life-threatening thrombocytopenia, potentially leading to hemorrhage. Thrombocytopenia was reported in patients with multiple myeloma (MM) and developed or worsened in patients with DLBCL.

    Thrombocytopenia is the leading cause of dosage modifications. Monitor platelet counts at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Institute platelet transfusion and/or other treatments as clinically indicated. Monitor patients for signs and symptoms of bleeding and evaluate promptly. Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.